Related Experiment Video

Updated: May 11, 2026

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
08:06

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

Common pathways to tumor rejection

Ena Wang1, Davide Bedognetti, Sara Tomei

  • 1Infectious Disease and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and trans-NIH Center for Human Immunology (CHI), National Institutes of Health, Bethesda, MD, USA.

Annals of the New York Academy of Sciences
|May 9, 2013
PubMed

Insights

Host immunosurveillance controls tumor growth via interferon pathways. A specific interferon-gamma signature and the immunologic constant of rejection (ICR) gene cluster are key to tumor rejection and immunotherapy response.

Area of Science:

  • Immunology
  • Oncology
  • Genetics

Background:

  • Host immunosurveillance, driven by interferon (IFN) pathways, is crucial for controlling tumor growth.
  • An IFN-gamma-related gene signature in tumors correlates with better prognosis and immunotherapy response.
  • This signature is linked to the immunologic constant of rejection (ICR), a gene cluster involved in tissue-specific immune destruction.

Purpose of the Study:

  • To summarize the understanding of the mechanisms behind tumor rejection.
  • To outline challenges in studying tumor rejection.
  • To propose a strategy for investigating the causes of tumor rejection.

Main Methods:

  • Review of existing research on IFN pathways and tumor immunosurveillance.
  • Analysis of the IFN-gamma signature and ICR gene cluster in various immune-mediated conditions.
  • Conceptual framework development for understanding tumor rejection.

Main Results:

  • The IFN-gamma signature and ICR are consistently associated with tumor rejection and favorable outcomes.
  • ICR activation is a conserved mechanism across autoimmunity, allograft rejection, and infection clearance.
  • Tumor rejection is presented as a conserved immune mechanism.

Conclusions:

  • Tumor rejection is part of a broader immune response conserved across different physiological and pathological conditions.
  • Understanding the IFN-gamma signature and ICR is vital for advancing cancer immunotherapy.
  • Further research strategies are proposed to elucidate the causes of tumor rejection.

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis07:45

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Published on: January 26, 2024

Related Concept Videos

Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...